In Re John P. Chupp

816 F.2d 643, 2 U.S.P.Q. 2d (BNA) 1437, 1987 U.S. App. LEXIS 222, 55 U.S.L.W. 2615
CourtCourt of Appeals for the Federal Circuit
DecidedApril 15, 1987
DocketAppeal 86-1631
StatusPublished
Cited by25 cases

This text of 816 F.2d 643 (In Re John P. Chupp) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re John P. Chupp, 816 F.2d 643, 2 U.S.P.Q. 2d (BNA) 1437, 1987 U.S. App. LEXIS 222, 55 U.S.L.W. 2615 (Fed. Cir. 1987).

Opinion

MARKEY, Chief Judge.

Appeal from a decision of the United States Patent and Trademark Office (PTO) Board of Patent Appeals and Interferences (board), affirming the examiner’s final rejection of claims 1 and 12 in application Serial No. 358,967 under 35 U.S.C. § 103. We reverse.

BACKGROUND

On March 17, 1982, John P. Chupp (Chupp) filed a continuation-in-part application, assigned to Monsanto Company, entitled “Herbicidal 2-Haloacetanilides.” The application contained 41 claims to a variety of chemical compounds within the generic class of 2-haloacetanilides, a method for using the compounds to combat weeds in crops, and an herbicidal composition containing a 2-haloacetanilide.

The examiner rejected all claims under 35 U.S.C. §§ 102(a) and 103, stating that the references, including Swiss patents 579,348 (issued July 31, 1976) and 585,191 (issued January 15, 1977) (Swiss patents), rendered the claimed compounds, methods and compositions prima facie obvious.

Chupp canceled all but eleven claims and limited the remaining claims to a single compound, N-(ethoxyrae£%Z )-2’-trifluoro-methyl-6’-methyl-2-chloroacetanilide. That compound differs by a single methylene group ( — CH2 — ) from the closest prior art compound, N-(ethoxyei%Z)-2’-trifluoromethyl-6’-methyl-2-chloroacetanilide, disclosed in the Swiss patents. Chupp apparently did not challenge the examiner’s conclusion that the Swiss patents rendered the claimed compound prima facie obvious.

To rebut the prima facie case of obviousness, Chupp submitted a declaration discussing the results of tests comparing the herbicidal activity of the claimed compound with that of the closest prior art compounds and with two commercial herbicides. The tests compared the compounds’ ability to control two weeds, quackgrass and yellow nutsedge, in two crops, corn and soybeans. It is undisputed that the claimed compound gave superior results, exhibiting selectivity factors (crop safety combined with weed-killing activity) at least five times greater than those of the closest prior art compounds. The declarant concluded “the herbicidal properties of the compound of the invention herein are unquestionably outstandingly superior to those of the relevant prior art; the unex *645 pected and unpredictable magnitude of superiority is evidenced by the many-fold increase in unit activity against weeds and high crop safety.”

The examiner finally rejected all claims under 35 U.S.C. § 103 as being unpatentable over the Swiss patents, saying that comparative testing using only two weeds and two crops was insufficient to establish unexpected herbicidal activity.

Chupp submitted two more declarations. The first presented data from a second comparative test of the claimed compound and the closest prior art compounds, again comparing their ability to control quack-grass and yellow nutsedge in corn and soybeans. The second declaration, from Dr. F.W. Slife, a University of Illinois agronomy professor, analyzed the results of both comparative tests and praised “the superior performance of the invention compound vis-a-vis the prior art compounds as completely unexpected considering the close chemical structure of the test compounds.”

The examiner allowed claims 36 and 37 for a method of combatting weeds in corn and soybeans using the claimed compound, but continued to reject the remaining claims. The examiner said that more extensive comparative testing was needed because the data disclosed in the specification showed the claimed compound would not be superior to prior art compounds for crops other than corn and soybeans.

Chupp appealed the rejection to the board, canceling all remaining rejected claims except 1 and 12. Claim 1 sets forth the compound and its structure. Claim 12 sets forth an “[hjerbicidal composition comprising an adjuvant and a herbicidally effective amount of the compound” and the compound’s structure.

The board affirmed the rejection of claims 1 and 12, holding that Chupp’s evidence was insufficient to rebut the prima facie case of obviousness. The board said the claimed compound had no “new or unexpected property”: The prior art compounds were selective herbicides, so it was no surprise that the claimed compound was also a selective herbicide. ** Prior art herbicides were useful in many crops; the specification data showed that the claimed compound was at best a run-of-the-mill performer in crops other than corn and soybeans. The board held that because the claims were limited to no particular weed or crop, “the showing is not fairly representative of that which is encompassed by the claims.” Therefore, concluded the board, the evidence of superiority in corn and soybeans could not rebut the prima facie obviousness of the “invention as a whole”.

The board further stated that Swiss patent 579,348 taught that N-alkoxymei%Z chloroacetanilides (like the claimed compound) were superior in activity to the corresponding N-alkoxyeí%¿ chloroacetanilides (like the closest prior art compound). Thus, said the board, “the results shown by appellant in his declaration are only those which would have been expected.”

ISSUE

Whether the board erred in sustaining the rejection of claims 1 and 12.

OPINION

It is undisputed that the claimed compound is novel. That its superior activity in com and soybeans is a new and unexpected property is confirmed by the allowance of the method claims to its use on com and soybeans. See In re McLamore, 379 F.2d 985, 988-90, 154 USPQ 114, 117-18 (CCPA 1967) (the grant of method claims persuasive of compound’s nonobviousness).

Chupp argues that this case is controlled by In re Papesch, 315 F.2d 381, 137 USPQ 43 (CCPA 1963), and the line of cases following it. In Papesch, one of our predecessor courts reversed a rejection of claims to compounds structurally similar to a prior art compound, but which unexpectedly possessed anti-inflammatory properties. The Papesch court held, “From the standpoint of patent law, a compound and all of its properties are inseparable; they *646 are one and the same thing.” 315 F.2d at 391, 137 USPQ at 51. Under the Papesch doctrine, evidence of unobvious or unexpected advantageous properties may rebut a prima facie case of obviousness based on structural similarities. Id. at 386-87, 137 USPQ at 48. Such evidence may include data showing that a compound is unexpectedly superior in a property it shares with prior art compounds. E.g., In re Lunsford,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Millennium Pharmaceuticals, Inc. v. Sandoz Inc.
862 F.3d 1356 (Federal Circuit, 2017)
Trustees of Columbia University v. Illumina, Inc.
620 F. App'x 916 (Federal Circuit, 2015)
Aventis Pharma S.A. v. Amphastar Pharmaceuticals, Inc.
525 F.3d 1334 (Federal Circuit, 2008)
Pfizer v. Apotex (Formerly Known as Torpharm)
488 F.3d 1377 (Federal Circuit, 2007)
Pfizer, Inc. v. Apotex, Inc.
480 F.3d 1348 (Federal Circuit, 2007)
Aventis Pharma S.A. v. Amphastar Pharmaceuticals, Inc.
475 F. Supp. 2d 970 (C.D. California, 2007)
Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc.
348 F. Supp. 2d 713 (N.D. West Virginia, 2004)
McNEIL-PPC, INC. v. L. Perrigo Co.
207 F. Supp. 2d 356 (E.D. Pennsylvania, 2002)
Saes Getters S.p.A. v. Ergenics, Inc.
816 F. Supp. 987 (D. New Jersey, 1992)
In Re Diane M. Dillon
919 F.2d 688 (Federal Circuit, 1990)
In Re Eli Lilly & Company
902 F.2d 943 (Federal Circuit, 1990)
Spalding & Evenflo Companies, Inc. v. Acushnet Co.
718 F. Supp. 1023 (D. Massachusetts, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
816 F.2d 643, 2 U.S.P.Q. 2d (BNA) 1437, 1987 U.S. App. LEXIS 222, 55 U.S.L.W. 2615, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-john-p-chupp-cafc-1987.